Bedrijfsoverzicht
Janux Therapeutics, Inc. operates as a clinical stage biopharmaceutical enterprise focused on the development of immunotherapies designed to treat cancer patients. The company utilizes proprietary technology platforms, specifically the Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) systems, to engineer its therapeutic candidates. This business falls within the Healthcare sector and the Biotechnology industry, positioning the firm to leverage advancements in immune system modulation for oncology treatments. With a market capitalization of $908.22 million, an annual revenue of $10.00 million, and an employee base of 109 individuals, the company represents a mid-sized entity in the biotechnology landscape. These valuation and revenue figures indicate that while the firm possesses a substantial asset base relative to its current income generation, it remains in a capital-intensive growth phase typical of clinical stage developers, where significant resources are allocated toward research and development rather than immediate profit generation.
Financiële gezondheid
The company reported a revenue of $10.00 million over the trailing twelve months, yet this figure stands in stark contrast to a net income of -$113,625,000, revealing a cost structure dominated by high burn rates common in early-stage biotechnology development. The EBITDA for the period was -$155,638,000, further illustrating that operating expenses far exceed the revenue generated from current operations. Free cash flow stood at -$51,267,876, indicating that the company is currently consuming cash reserves to fund its clinical trials and operational activities, which limits immediate financial flexibility but is necessary for reaching commercial milestones. The gross margin is listed at 0.0%, the operating margin is -1576.7%, and the profit margin is 0.0%, reflecting a financial reality where revenue does not yet cover the substantial costs of goods sold and research expenditures. The company holds $966.57 million in cash against $22.14 million in debt, resulting in a debt-to-equity ratio of 2.31, which suggests a balance sheet that is heavily weighted toward equity financing rather than traditional leverage. Despite the high debt-to-equity figure, the current ratio of 39.04 demonstrates an extremely robust short-term liquidity position, allowing the firm to easily meet its obligations with current assets. The return on equity is -11.5% and the return on assets is -9.6%, metrics that reveal management is currently generating negative returns on the capital invested in the company as it scales its clinical pipeline.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to the lack of positive net income, while the forward P/E is calculated at -4.28, implying that the market anticipates a continued period of negative earnings before the company potentially achieves profitability. The price-to-book ratio is 0.94, suggesting that the market values the company's equity at a slight discount to its accounting book value. The price-to-sales ratio stands at 90.82 and the EV/EBITDA is 0.23, indicating that the valuation is heavily driven by sales multiples rather than earnings power, a standard metric interpretation for unprofitable biotechnology firms where future potential is priced into the stock. The stock has traded within a 52-week range bounded by a high of $35.34 and a low of $12.12. Without the current share price explicitly provided in the facts to calculate a precise percentage, the trading range highlights the significant volatility experienced by the stock over the last year. The beta is 2.81, which means the stock price is expected to exhibit volatility nearly three times greater than that of the broader market, reflecting the high risk profile associated with clinical stage biotechnology investments.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is in a start-up phase where historical growth rates are not yet established for comparison. Because the company reports a net loss and a payout ratio of 0.0%, it does not distribute dividends to shareholders, meaning the dividend yield is N/A. Consequently, the company reinvests all available resources and retained earnings directly into expanding its clinical pipeline and research initiatives rather than providing income distributions. The overall growth and income profile is characterized by a lack of current earnings growth or dividend income, with the primary focus remaining on capitalizing on the potential future value of its immunotherapy platforms.